

- (51) International Patent Classification:
C12N 15/867 (2006.01) A61P 35/00 (2006.01)
- (21) International Application Number:
PCT/US2023/078732
- (22) International Filing Date:
03 November 2023 (03.11.2023)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
63/422,678 04 November 2022 (04.11.2022) US
63/422,920 04 November 2022 (04.11.2022) US
63/487,784 01 March 2023 (01.03.2023) US
63/466,471 15 May 2023 (15.05.2023) US
63/579,188 28 August 2023 (28.08.2023) US
- (71) Applicant: UMOJA BIOPHARMA, INC. [US/US]; 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US).
- (72) Inventor; and
(71) Applicant: MITTELSTEADT, Kristen [US/US]; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US).
- (72) Inventors: NICOLAI, Christopher; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US). TANG, Weiliang; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US). RYU, Byoung; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US). LARSON, Ryan; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US). QIN, Jim; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US). LEUNG, Wai-Hang; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US). PARK, Lisa, Yun; c/o Umoja Biopharma, Inc., 1616 Eastlake Ave E., Suite 550, Seattle, WA 98102 (US).
- (74) Agent: MIRON, Anna et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: LENTIVIRAL PARTICLES DISPLAYING FUSION MOLECULES AND USES THEREOF




Fig. 1A

(57) Abstract: Provided herein are particles comprising polynucleotide constructs for generating cells expressing anti-CD19 chimeric antigen receptor, as well as vectors, such as lentiviral vectors, comprising same, cells comprising same, and methods of using same.

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*